Lara Bloom | President and CEO
The Ehlers-Danlos Society

Lara Bloom, President and CEO, The Ehlers-Danlos Society

Lara Bloom is President and CEO of The Ehlers-Danlos Society, where she leads global efforts to raise awareness of rare, chronic, and invisible conditions—specializing in Ehlers-Danlos syndromes (EDS), hypermobility spectrum disorders (HSD), and related conditions. She spearheads international medical collaboration, research funding, education, and advocacy.    A passionate leader in patient engagement and global collaboration, Lara was appointed Academic Affiliate Professor of Practice at Penn State College of Medicine in March 2020, marking a decade of work in patient advocacy. She is widely published and a sought-after keynote speaker at conferences, policy forums, academic lectures, and corporate events.    Lara serves as Vice-Chair of the Board of the International Alliance of Patients’ Organizations (IAPO) and is a Board Member of Genetic Alliance UK.    In June 2025, she received the prestigious Made with Patients Award at the Patient Engagement Open Forum (PEOF), honoring her leadership in shaping truly patient-centered global advocacy. She was also named a 2025 D-30 Disability List Honoree by Diversability, recognizing her as a prominent voice in the disability and rare disease space.   

Appearances:



Pre-Congress Workshops - Monday 27th October @ 10:00

A Complicated Challenge: What Ehlers Danlos Syndrome Teaches About Trust, Trauma and Trial Design

This interactive session explores how historical clinical challenges, and the Ehlers Danlos patient experience should challenge us to rethink how we define inclusion, eligibility and trustworthiness in clinical research and AI.  What authentic steps can industry take to “heal the harm” and promote safer practices in RWE and AI? How can we rebuild trust and design patient informed programs with communities that have been marginalized or misunderstood?

Pre-Congress Workshops - Monday 27th October @ 14:00

Accelerating a patient powered pathway from development to market in Europe with rare therapies

2-3 PM:- Early/Expanded Access Programs: Explore ways to better execute EAPs in Europe that ensure an optimized experience, from patient discovery to engagement.

Moderator: Andrew Cummins, Vice President, Business Development, Sciensus 

Panel: Jim McGrath, Director of Commercial Policy, Irish Pharmaceutical Healthcare Association

-------------------------------------------------------------------------------------------------------------------------------------

3-4 PM:- Regulatory, Pricing, and Market Authorisation: How best to navigate the complex European environment to ensure the best approach and successful execution of these critical components of the development journey.

Moderator: Doug Niven, European Strategic Consultant, Sciensus

Panel: Andrew Cummins, Vice President, Business Development, Sciensus 

Ralph Hughes, Chief Business Officer, Faron Pharmaceuticals

-------------------------------------------------------------------------------------------------------------------------------------

4-5 PM:- Patient Engagement and In-Market Support: What are best practices for patient-focused support programs, distribution, and digital solutions post-approval and in-market.

Moderator: Ray Huml, Vice President of Rare Strategy, Sciensus 

Panel: Mathieu Loiseau, Director of Rare Clinical Services, Sciensus

Patricia Furlong, Preseident, PPMD

Lara Bloom, CEO, Ehlers-Danlos Society

Sophie Muir, Chair of Trustees, Timothy Syndrome Alliance

Session led by: Sciensus

Day 1 - Tuesday 28 October @ 16:50

Panel: Driving Patient-Centric Innovation: Pharma’s Involvement and Stakeholder Collaboration

last published: 17/Oct/25 17:25 GMT

back to speakers

Get involved at World Orphan Drug Congress Europe 2025

 

 

TO SPONSOR


Steph Scanlon

Steph.Scanlon@terrapinn.com

 

TO SPEAK


Abdu Kauroo
Abdu.Kauroo@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.